Archive for November, 2013

Company allegedly used a phony engineer to defame its competitor

AVEPOINT, INC. v.  AXCELER UNITED STATES DISTRICT COURT  WD VA Civil Action No. 7:13CV00035 AvePoint alleges that Axceler and its agents, including Burns, have engaged in a campaign of making false, defamatory, and deceptive claims  and statements...

Read More

First FDA Authorization for Next-Generation Sequencer NEJM

Francis S. Collins, M.D., Ph.D., and Margaret A. Hamburg, M.D. November 19, 2013DOI: 10.1056/NEJMp1314561 “… today the Food and Drug Administration (FDA) has granted marketing authorization for the first high-throughput (next-generation) genomic sequencer, Illumina’s...

Read More

Making Medical Decisions for Patients without Surrogates NEJM

http://www.nejm.org/doi/full/10.1056/NEJMp1308197?query=TOC Thaddeus Mason Pope, J.D., Ph.D. N Engl J Med 2013; 369:1976-1978November 21, 2013DOI: 10.1056/NEJMp1308197 “People who are decisionally incapacitated but haven’t provided advance directives for their health care and have no health care...

Read More

Baptist Health Systems Settles Federal False Claims Act Civil Lawsuit

Baptist Health Systems, one of the largest health care providers in San Antonio, has paid $3,675,000 to the United States Department of Justice to settle allegations that it violated the federal False Claims Act...

Read More

OIG report on biobank risks

Biobanks are repositories of biospecimens—and, in some cases, associated personally identifiable information (PII) and personal health information—to be used for research purposes. Such research must comply with Federal regulations governing human subjects research. An...

Read More

Publication of Trials Funded by the National Heart, Lung, and Blood Institute

David Gordon, M.D., Ph.D., Wendy Taddei-Peters, Ph.D., Alice Mascette, M.D., Melissa Antman, Ph.D., Peter G. Kaufmann, Ph.D., and Michael S. Lauer, M.D. N Engl J Med 2013; 369:1926-1934November 14, 2013DOI: 10.1056/NEJMsa1300237 “Rapid publication of...

Read More

Expediting Drug Development — The FDA’s New “Breakthrough Therapy” Designation

Rachel E. Sherman, M.D., M.P.H., Jun Li, J.D., Ph.D., Stephanie Shapley, M.B.A., Melissa Robb, R.N., and Janet Woodcock, M.D. N Engl J Med 2013; 369:1877-1880November 14, 2013DOI: 10.1056/NEJMp1311439 “Many people with serious or life-threatening...

Read More

COURT REVOKES 501(C)(3) STATUS OVER “SCRIP” PROGRAM THAT PROVIDED REDUCED DUES TO PARTICIPATING MEMBERS: EXEMPT ORGANIZATIONS SHOULD REVIEW FUNDRAISING ACTIVITIES AND MEMBER DISCOUNTS

http://www.reinhartlaw.com/Pages/default.aspx Something for all booster clubs to watch. non profit revocation

Read More

Law Firm Non-compete case

“A Virginia law firm is trading charges in court with two former associates after the pair jumped ship and started their own competing law firm. A prominent feature of the lawyers’ employment contracts is...

Read More

Medical research and students in Latin America

The Lancet, Volume 382, Issue 9904, Page 1553, 9 November 2013 <Previous Article|Next Article> doi:10.1016/S0140-6736(13)62324-7Cite or Link Using DOI Copyright © 2013 Elsevier Ltd All rights reserved. “Patricio Alfaro-Toloza a, Romina Olmos-de-Aguilera a Undergraduate medical students are encouraged to do...

Read More